Impact of Nuclear Oestrogen Receptor Beta Expression in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy.

Introduction Oestrogen receptor beta (ER-ß) is abundantly expressed in breast cancer (BC), but its impact on neoadjuvant chemotherapy outcome is unknown. Patients and Methods Patients treated in the neoadjuvant GeparTrio trial with available tissue for immunohistochemical analyses were included. Nuclear ER-ß expression was correlated with clinico-pathologic characteristics. The impact of its expression on pathological complete response (pCR [ypT0/ypN0]) and survival was determined. Results Samples of 570 patients were available. Low nuclear ER-ß expression (IRS < 9) was observed in 48.4% of hormone receptor positive and 58.6% of hormone receptor negative tumours. Low nuclear ER-ß expression was associated with higher pCR rates compared to high nuclear ER-ß expression (16.1% vs. 4.7%, p = 0.026). Low ER-ß expression was no independent predictor of pCR in multivariate analyses. Disease-free and overall survival were not statistically different between patients with high and low nuclear ER-ß expression. Triple-negative BCs showed low nuclear ER-ß expression in 57.7%, and pCR rates were 27.1% and 0% (p = 0.23) in low and high ER-ß expressing tumours, respectively. Conclusion Low ER-ß expression is associated with improved pCR rates in univariate analyses. However multivariate analyses and survival analyses do not indicate an impact of ER-ß on survival in patients undergoing neoadjuvant chemotherapy. Further examination of ER-ß as predictor for endocrine therapy might be of value.